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Abstract
Introduction: Smooth muscle tumors of uncertain malignant potential represent a histologically heterogeneous
group of uterine smooth muscle tumors that cannot be diagnosed as either benign or malignant. Smooth muscle
tumors of uncertain malignant potential are usually clinically benign, but should be considered tumors of low
malignant potential because they can occasionally recur or metastasize to distant sites.
Case presentation: We report the case of a 62-year-old Mongol woman diagnosed with a retroperitoneal smooth
muscle tumor of uncertain malignant potential and lung metastasis, with a history of prior hysterectomy. The case
was initially misdiagnosed as retroperitoneal sarcoma, and our patient received chemotherapy. However, no
interval change in the size of the retroperitoneal mass and metastatic lung nodules was seen over a period of at
least five years. She underwent partial resection of the retroperitoneal mass for the purposes of debulking and
establishing a histopathological diagnosis. The diagnosis of the retroperitoneal mass was then confirmed as a
smooth muscle tumor of uncertain malignant potential.
Conclusion: Smooth muscle tumors of uncertain malignant potential have an unpredictable clinical course, and
relapses generally appear to occur after a long disease-free interval of up to several years. Therefore, patients
diagnosed with smooth muscle tumors of uncertain malignant potential should receive long-term follow-up.
Introduction
Smooth muscle tumors are histologically categorized
into leiomyomas and leiomyosarcomas, based on the
combination of histological parameters such as mitotic
activity, cytological atypia and coagulative tumor cell
necrosis [1]. Smooth muscle tumors of uncertain malig-
nant potential (STUMPs) represent a histologically het-
erogeneous group of uterine smooth muscle tumors that
do not clearly fall into the category of either leiomyomas
or leiomyosarcomas [2]. The clinical behavior of
STUMPs is poorly understood. In previous reports in
the literature, most uterine STUMPs had a benign clini-
cal course and were successfully treated with myomect-
omy or hysterectomy. We report the case of a 62-year-
old woman who presented to our facility with a
retroperitoneal STUMP with lung metastasis, eight years
after a hysterectomy.
Case presentation
A 62-year-old Mongol woman was referred to our hos-
pital for further evaluation of an intra-abdominal mass
seen on an abdominal computed tomography (CT) scan.
She had visited her primary care physician for recently
aggravated chronic constipation and intermittent
abdominal discomfort. These symptoms had persisted
for more than 20 years. Whenever these symptoms were
exacerbated, she took medications such as painkillers
and laxatives prescribed by several private hospitals. She
had no other gastrointestinal symptoms, and there was
no change in body weight. Additionally, there were no
respiratory or cardiovascular symptoms.
Her medical history was significant for the following
illnesses. In 1994, she attended hospital for intermittent
lower abdominal pain and constipation; on this occasion
she was found to have a large retroperitoneal mass on
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an abdominal CT scan. Additionally, a chest CT scan
showed small, well defined nodular lesions in both per-
ipheral lung fields. A sonography-guided fine needle
aspiration biopsy of the retroperitoneal mass was per-
formed. The cytological findings revealed an atypical
spindle cell tumor, and differential diagnoses of malig-
nant fibrous histiocytoma, leiomyosarcoma, fibrosar-
coma and malignant schwannoma were considered. At
that time, she was diagnosed with retroperitoneal sar-
coma with lung metastases. She received six cycles of
ifosfamide (1440 mg/m2 on days one to five) and etopo-
side (80 mg/m2 on days one to five). After completion
of the planned chemotherapy, there were no significant
interval changes in the size of the retroperitoneal mass.
Additionally, she received six cycles of CYVADIC
(cyclophosphamide 500 mg/m2, doxorubicin 50 mg/m2,
vincristine 1.5 mg/m2 on day one, dacarbazine 250 mg/
m2 on days one to five) chemotherapy. She was then
lost to follow-up and had received no further treatment
since then.
In November 2005 and January 2007, she visited the
Department of Respiratory Medicine at our hospital due
to symptoms of upper respiratory infection. She under-
went abdominal and chest CT scans on both these vis-
its. Between 2005 and 2007, her CT findings showed no
significant change in the size of the retroperitoneal mass
and lung metastatic nodules. At eight years before the
diagnosis of retroperitoneal sarcoma was established,
she had undergone a total hysterectomy for uterine leio-
myoma at Korea Cancer Center Hospital, Seoul, Korea.
Apart from these incidents, she had no other medical
problems and her family history was unremarkable. She
had no history of alcohol use or smoking.
On physical examination, her breath sounds were
clear and there were no palpable lymph nodes. Her
abdomen was soft and obese, and there was no abdom-
inal tenderness on palpation. No abdominal masses
were identified on palpation, and there was no organo-
megaly. Her blood pressure was 140/90 mmHg, hemo-
globin concentration was 15.6 g/dL, white blood cell
count was 7600 cells/μL, and platelet count was 205,000
cells/μL. Her serum lactate dehydrogenase (LDH) level
was mildly increased to 564 U/L. Other laboratory find-
ings were within their normal ranges. Serum levels of
tumor markers cancer antigen (CA) 125, CA 19-9, and
carcinoembryonic antigen (CEA) were normal. An
abdominal CT scan showed multiple large, well defined,
highly enhanced masses in the retroperitoneum and pel-
vic cavity, and there were no significant changes in the
sizes of the masses since November 2005 (Figure 1). A
chest CT scan showed multiple, tiny to small cavitary
and cystic metastatic nodules in both lungs, and there
was also no interval change since November 2005 (Fig-
ure 1). There was no significant mediastinal or hilar
lymphadenopathy. A F-18 fluorodeoxyglucose positron
emission tomography/computed tomography (F-18 FDG
PET/CT) scan showed conglomerated bulky masses with
inhomogeneous FDG uptake (maximum standard uptake
value (SUVmax) of 4.0) in the retroperitoneum and pel-
vic cavity. We planned to perform a CT-guided percuta-
neous lung biopsy, but her pulmonary lesions were too
small to be biopsied. Therefore, a partial resection of
the retroperitoneal mass was performed for the purposes
of debulking and establishing a histopathological diagno-
sis. During surgery, a huge, fixed, hard mass with a
smooth surface was found around the abdominal aorta;
this mass was hypervascular and fixed. A retroperitoneal
mass of size 12.2 × 6.3 × 4.5 cm was removed. On gross
examination, the retroperitoneal mass weighed 283g and
was a pale brown color with a whitish homogeneous cut
surface. Microscopically, the resected mass was charac-
terized by spindle cell proliferation. Immunohistochem-
ical (IHC) staining for pancytokeratin (AE1/AE3),
CD117, PDGFR, CD34, actin, desmin, and S-100 protein
was performed. IHC staining results were positive for
actin and desmin (Figure 2). The mitotic activity was <
1 mitosis event per 50 high-power fields (HPFs) with
mild to focally moderate nuclear atypia and there was
no evidence of tumor cell necrosis. The final pathologi-
cal diagnosis was a retroperitoneal STUMP tumor, with
a recommendation for careful clinical follow-up. Addi-
tional IHC staining for Ki-67, p53, estrogen receptor
(ER), and progesterone receptor (PR) was performed.
The Ki-67 labeling index was less than 5%, and results
were negative for p53. IHC staining results for both ER
and PR were positive (Figure 2). We considered
angioembolization as treatment for the tumors because
of the tumor hypervascularity. Angioembolization was
performed with polyvinyl alcohol particles (Boston
Scientific, Fremont, California, USA) and multiple
microcoils (Tornado, Cook, Bloomington, IN, USA)
twice in five months. Both the lumbar arteries, the right
internal iliac artery and the left renal capsular artery
supplying the tumors were embolized. At one month
after the last angioembolization, an abdominal CT scan
was performed. There was no significant interval change
in the size and extent of the retroperitoneal masses.
Discussion
The major histopathological parameters for assessing the
diagnosis and prognosis of smooth muscle tumors are
cytological atypia, mitotic index, and coagulative tumor
cell necrosis. Based on these parameters, the definition
proposed by Bell et al. is as follows [3]. Leiomyosarco-
mas are defined as tumors with at least two of the fol-
lowing three features: diffuse cytological atypia, tumor
cell necrosis, and ≥ 10 mitosis events per 10HPFs. Leio-
myomas are defined as tumors with no or mild
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cytological atypia, no tumor cell necrosis, and < 5 mito-
sis events per 10HPFs. STUMPs are defined as tumors
with following features: (1) focal moderate to severe
cytological atypia, no tumor cell necrosis, and < 5 mito-
sis events per 10HPFs, or (2) no or mild cytological aty-
pia, tumor cell necrosis, < 10 mitosis events per 10HPFs.
STUMPs are relatively rare tumors. The data available
on clinical characteristics, biological behavior, and fol-
low-up is insufficient, and therefore it is difficult to pre-
dict the clinical course of STUMPs. Guntupalli et al.
reported the follow-up data of 41 patients diagnosed
with uterine STUMPs [3]. The mean follow-up time was
45 months (range one to 171 months). Three patients
(7.3%) had a recurrence during the follow-up period,
one patient presented with a pelvic mass and a pulmon-
ary nodule, and two patients presented with retroperito-
neal and pelvic masses. They developed recurrent
disease at 13, 47, and 68 months, respectively, after the
initial surgical intervention. Berretta et al. also presented
a report of three cases with STUMPs [1]. During the
Figure 1 Computed tomography (CT) scan results. (a, b) Abdominal CT scan showing 8.8 × 16.7 cm sized multilobulated, well defined
enhanced masses in retroperitoneal space. (c, d) Chest CT scan showing multiple tiny to small solid, cavitary metastatic nodules in both lungs.
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follow-up, one patient developed diffuse lung metastases
nine years after the original diagnosis. The patient was
then treated with gonadotropin-releasing hormone ago-
nists and an aromatase inhibitor. Amant et al. reported
a retroperitoneal/pelvic relapse after four years in a
patient diagnosed with a STUMP and treated with
hysterectomy and adnexectomy. This patient experi-
enced a relapse of leiomyosarcoma with a malignant
evolution of the primary tumor [4]. As mentioned
above, previous studies suggest that STUMPs are usually
clinically benign, but they should be considered as
tumors of low malignant potential because they can
Figure 2 Histological appearance of the retroperitoneal smooth muscle tumor of uncertain malignant potential (STUMP). Spindle cell
proliferation ((a) hematoxylin and eosin, 200 ×) with mild to moderate nuclear atypia ((b) hematoxylin and eosin, 400 ×). (c, d)
Immunohistochemical staining for actin and desmin (200 ×). (e, f) Immunohistochemical staining for estrogen receptor (ER), and progesterone
receptor (PR) (200 ×).
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occasionally recur or metastasize to distant sites, years
after hysterectomy [2]. Therefore, patients diagnosed
with STUMPs should receive long-term follow-up.
Our patient also developed a retroperitoneal recur-
rence with lung metastases, eight years after her hyster-
ectomy. Although we could not confirm the pathology
of the previous hysterectomy specimens, the retroperito-
neal mass showed a strong positivity for ER and PR.
This hormone receptor positivity could be useful to
determine whether a retroperitoneal smooth muscle
tumor is of uterine type, because the extrauterine soft
tissue smooth muscle tumors are generally ER/PR nega-
tive [5,6]. Lung metastases were not confirmed by histo-
pathology, but our patient’s pulmonary lesions were
consistent with typical cavitating metastatic nodules,
which had been reported in the previous literature.
Additionally, she had no other respiratory symptoms
or laboratory findings suggestive of other pulmonary
diseases.
There are some studies on the molecular markers or
cytological/histological patterns that are predictive of
the clinical course of STUMP. Burns et al. reported on
the importance of coagulative tumor cell necrosis as the
single most powerful factor for malignant behavior
among morphological features [7]. Some studies have
emphasized the importance of Ki-67, as a proliferation
marker and p53 overexpression that indicates p53
tumor suppressor gene mutation [8]. Overexpression of
p53 and a high Ki-67 labeling index are frequently asso-
ciated with leiomyosarcoma, and therefore these mar-
kers may be useful IHC parameters to distinguish
between cases of malignant smooth muscle tumors and
those of uncertain or borderline histology. Some studies
also have reported that ER/PR-positive tumors showed a
benign clinical behavior in contrast with markedly
reduced hormone receptor positivity in leiomyosarcoma
[4,8].
The lesion in our patient’s case showed focal moderate
nuclear atypia, but mitosis activity was < 1 mitosis event
per 50HPFs without necrosis. Additionally, the lesion
was p53 negative with low Ki-67 expression and was
ER/PR positive. Therefore, it can be expected to be a
STUMP of low malignant potential. In fact, the retro-
peritoneal mass and metastatic lung nodules showed no
interval change in their size over a period of at least five
years. However, the multiple lung metastases were an
unusual finding that was unlike its benign clinical
course.
There is no consensus on the preferred management
of benign metastasizing leiomyoma or STUMP with
inoperable metastatic lesions. Some studies support the
hormonal dependency of uterine smooth muscle tumor,
and have revealed the effects of medical castration (that
is, suppression of the production of estrogen) [9,10].
The role of chemotherapy in these tumors with a benign
nature remains uncertain. We tried angioembolization in
the treatment of our patient’s inoperable retroperitoneal
STUMP, since the tumor showed hypervascularity.
However, there was no decrease in the size of the
tumors on a follow-up CT scan. We hypothesized that
angioembolization was less effective in reducing tumor
masses in our patient due to multiple, numerous, min-
ute feeding arteries from both the intra-peritoneal and
retroperitoneal branches of the abdominal aorta and
both the iliac arteries.
Conclusion
STUMPs have an unpredictable clinical course. On the
basis of our experience and review of the literature,
relapses appear to occur generally after a long disease-
free interval of up to several years. Therefore, in the
patients with STUMPs, a long-term, close follow-up is
required. The focus of future research should be on
finding the markers based on better understanding of
the molecular pathways leading to malignant transfor-
mation, which will allow us to predict the clinical beha-
vior of these tumors of uncertain malignant potential.
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